Judges picked TrialSpark as the winner on the life sciences track of the pitch competition at MedCity's virtual precision medicine conference. While the company is focused on improving clinical trials for others, it hopes eventually to bring drugs of its own to market.
5AM Ventures and RA Capital Management led the round. The company is developing hematopoietic stem cells engineered to be protected from targeted immunotherapies.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
As people get older, they are are more at risk for the major causes of death, like heart disease, stroke, certain cancers, and Alzheimer’s. But some researchers are looking at ways to take the age factor out of the picture, at least a little bit. A new study, according to IFLScience, is looking at a […]